Summary
Becton, Dickinson and Company (BDX) reported its fiscal second quarter 2017 results, showcasing a slight decrease in revenue primarily due to the divestiture of its Respiratory Solutions business. Despite this, the company demonstrated resilience with volume growth in its continuing operations, particularly in the Medical and Life Sciences segments. The company highlighted ongoing investments in research and development and geographic expansion as drivers for future growth. Financially, BDX maintained a strong position with solid operating cash flows, enabling continued returns to shareholders through dividends and share repurchases. A significant development announced post-quarter was the definitive agreement to acquire C.R. Bard, Inc., a move expected to create a leading medical technology company. The company navigated a complex operating environment, including foreign currency translation headwinds, but emphasized its ability to adapt and grow its core businesses. The financial results were also impacted by specific items, including a significant reversal of litigation reserves due to a favorable appellate court decision, which boosted net income. Investors should note the strategic direction towards enhanced market position through acquisitions, alongside disciplined operational execution.
Financial Highlights
53 data points| Revenue | $2.97B |
| Cost of Revenue | $1.54B |
| Gross Profit | $1.43B |
| R&D Expenses | $187.00M |
| SG&A Expenses | $724.00M |
| Operating Expenses | $2.52B |
| Operating Income | $446.00M |
| Interest Expense | $86.00M |
| Net Income | $344.00M |
| EPS (Basic) | $1.61 |
| EPS (Diluted) | $1.58 |
| Shares Outstanding (Basic) | 213.58M |
| Shares Outstanding (Diluted) | 217.87M |
Key Highlights
- 1Total revenues decreased by 3.2% to $2.969 billion, primarily impacted by the divestiture of the Respiratory Solutions business.
- 2Continuing businesses showed volume growth of over 5% for the quarter, driven by the Medical and Life Sciences segments.
- 3Net income increased to $344 million, or $1.58 per diluted share, benefiting from a $336 million reversal of litigation reserves.
- 4Operating cash flow for the first six months of fiscal year 2017 was $1.040 billion, demonstrating strong cash generation.
- 5The company repurchased approximately $220 million of common stock under an accelerated share repurchase agreement.
- 6BD announced a definitive agreement to acquire C.R. Bard, Inc. for approximately $24 billion, a significant strategic move expected to close in the fall of 2017.
- 7Effective tax rate decreased significantly in the three-month period due to tax benefits from share-based compensation and favorable tax audit settlements.